Zhenyu Zhu

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Acoustic "re-charging" of nanofiber air filters.

Acoustic "re-charging" of nanofiber air filters.

Journal: Materials horizons

Published: March 18, 2026

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.

Journal: Journal for immunotherapy of cancer

Published: January 28, 2026

Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study.

Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study.

Journal: Chinese medical journal

Published: December 02, 2025

Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study.

Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study.

Journal: Cancer immunology, immunotherapy : CII

Published: August 28, 2025

Icaritin Sensitizes Hepatocellular Carcinoma to PD-L1 Therapy by NQO1-Dependent Ferroptosis Induction.

Icaritin Sensitizes Hepatocellular Carcinoma to PD-L1 Therapy by NQO1-Dependent Ferroptosis Induction.

Journal: Phytotherapy research : PTR

Published: August 15, 2025

Icaritin Sensitizes Hepatocellular Carcinoma to PD-L1 Therapy by NQO1-Dependent Ferroptosis Induction.

Icaritin Sensitizes Hepatocellular Carcinoma to PD-L1 Therapy by NQO1-Dependent Ferroptosis Induction.

Journal: Phytotherapy research : PTR

Published: August 15, 2025

Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer.

Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: August 07, 2025

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study.

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study.

Journal: Cancer immunology, immunotherapy : CII

Published: May 27, 2025

Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.

Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.

Journal: Cancer immunology, immunotherapy : CII

Published: March 03, 2025

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Journal: Hepatobiliary surgery and nutrition

Published: February 28, 2025

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Journal: Bioscience trends

Published: December 25, 2024

A Review of High-Temperature Resistant Silica Aerogels: Structural Evolution and Thermal Stability Optimization.

A Review of High-Temperature Resistant Silica Aerogels: Structural Evolution and Thermal Stability Optimization.

Journal: Gels (Basel, Switzerland)

Published: December 05, 2024

Showing 1-12 of 50

Last Updated: 09/26/2026